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Summary
Description: The Amyotrophic Lateral Sclerosis Functional
Rating Scale-revised (ALSFRS-R) is a self-reported questionnaire
that measures physical function in patients with amyotrophic
lateral sclerosis.1 The ALSFRS-R is the most commonly used
functional rating instrument in clinical practice and clinical trials.
In amyotrophic lateral sclerosis, reduced physical function and
the rate of decline are used as markers of disease severity and
disease progression. The ALSFRS-R is easy to use and can be
administered within 10 minutes. Furthermore, ALSFRS-R has
been adapted for online,2 telephone,3,4 and self-administration,5
and is translated into several languages.6–9
Instructions for completing and scoring: The ALSFRS-R is a
12-item rating scale across four functional domains: fine motor,
gross motor, bulbar and respiratory function. Each item consists
of five possible responses (0 = unable to perform the task to
4 = normal functioning). The 12 items address daily living
activities: speech, salivation, swallowing, handwriting, preparing
food, dressing, bed mobility, walking, climbing stairs, dyspnoea,
orthopnoea, and breathing. Conventionally, individual item
scores are added to yield a combined score between 0 and 48
(maximum score). However, due to the heterogeneity and
multidimensionality of amyotrophic lateral sclerosis, it is
recommended that domain-specific subscores be reported, as
they provide better prognostic value and more accurately reflect
disease severity.10,11 In fact, univariate analysis has identified
that an ALSFRS-R respiratory subscore of < 10 at initial assess-
ment is an adverse prognostic marker in amyotrophic lateral
sclerosis.12
The rate of change of the ALSFRS-R score (termed the ‘ALSFRS-R
slope’) has also been shown to be an acceptable prognostic
indicator.12–14 The total ALSFRS-R slope can be calculated using the
formula:
48  ðTotal ALSFRS-R score at initial assessmentÞ
time from onset to initial assessment ðmonthsÞ
In addition, subscore slopes can be calculated by subtracting
each subscore from the maximum subscore possible in each
functional domain (eg, 12 for bulbar and respiratory, and 24 for
motor combined) divided by symptom duration. Assessment of
specific subscore slopes is important when considering the
differing rates of decline between bulbar-onset and spinal-onset
patients.11
Prognosis and survival: The ALSFRS-R slope has been
identified as an independent predictor of survival (hazard ratio
(HR) = 2.8)13 and a sensitive prognostic biomarker.12 A higher
ALSFRS-R slope score ( 1point/month) indicates faster function-
al decline and is associated with shorter survival.12,13 More
specifically, a slope of < 0.47 at initial assessment is predictive of
a longer survival (median survival of 2.4 years, HR = 1), compared
with a slope score between 0.47 and 1.11 (median survival
1.6 years, HR = 1.77), or a slope score that is > 1.11, which has the
poorest survival (median survival 0.7 years, HR = 3.74).12
Reliability and validity: The ALSFRS-R has demonstrated
good to excellent inter-rater (ICC = 0.87 to 0.97), intra-rater
(ICC = 0.93 to 0.97), and test-retest reliability (ICC = 0.975,
r = 0.85 to 0.91).1,3,5–9,15 The 12-item subscale shows good
internal consistency (Cronbach’s alpha = 0.71 to 0.93)1,7,8 but
the sum of items to a total score shows weak factorial validity
and poor unidimensionality.16–18 Reporting subscores to provide
a disease profile instead of a single combined score is strongly
recommended.10,11 Furthermore, there are contrasting views
about whether four or three subscales exist by combining fine
and gross motor function into a single ‘motor’ domain. Rasch
analysis of the ALSFRS-R has identified three domains,17,18
although an exploratory factor analysis indicates that four
domains with two cross-loading items (bed mobility, dressing) is
superior.10
Commentary
Current evidence suggests that the ALSFRS-R constitutes a
profile of functional domain subscores rather than a single (total)
score representing disease severity, and the slope of ALSFRS-R has
important prognostic value. The popularity of the ALSFRS-R is
likely due to its ease of use, minimal training required, low cost,
and shortage of other recognised biomarkers to quantify disease
progression. Further development of the ALSFRS-R and its
subscales is required to ensure adequate measurement proper-
ties,10,17 and future research should determine sensitivity to
treatment outcomes.
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